PL2337849T3 - Zmutowany polipeptyd czynnika ix, jego zastosowania i sposób jego otrzymywania - Google Patents

Zmutowany polipeptyd czynnika ix, jego zastosowania i sposób jego otrzymywania

Info

Publication number
PL2337849T3
PL2337849T3 PL09748260T PL09748260T PL2337849T3 PL 2337849 T3 PL2337849 T3 PL 2337849T3 PL 09748260 T PL09748260 T PL 09748260T PL 09748260 T PL09748260 T PL 09748260T PL 2337849 T3 PL2337849 T3 PL 2337849T3
Authority
PL
Poland
Prior art keywords
factor
production
polypeptide mutant
mutant
polypeptide
Prior art date
Application number
PL09748260T
Other languages
English (en)
Inventor
Paolo Simioni
Original Assignee
Uniqure Biopharma B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41397565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2337849(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from ITBO2008A000564A external-priority patent/IT1394177B1/it
Priority claimed from ITBO2009A000275A external-priority patent/IT1395980B1/it
Application filed by Uniqure Biopharma B.V. filed Critical Uniqure Biopharma B.V.
Publication of PL2337849T3 publication Critical patent/PL2337849T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL09748260T 2008-09-15 2009-09-15 Zmutowany polipeptyd czynnika ix, jego zastosowania i sposób jego otrzymywania PL2337849T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITBO2008A000564A IT1394177B1 (it) 2008-09-15 2008-09-15 Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
ITBO2009A000275A IT1395980B1 (it) 2009-05-06 2009-05-06 Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
EP09748260.8A EP2337849B1 (en) 2008-09-15 2009-09-15 Factor ix polypeptide mutant, its uses and a method for its production
PCT/EP2009/061935 WO2010029178A1 (en) 2008-09-15 2009-09-15 Factor ix polypeptide mutant, its uses and a method for its production

Publications (1)

Publication Number Publication Date
PL2337849T3 true PL2337849T3 (pl) 2018-11-30

Family

ID=41397565

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09748260T PL2337849T3 (pl) 2008-09-15 2009-09-15 Zmutowany polipeptyd czynnika ix, jego zastosowania i sposób jego otrzymywania
PL19174517.3T PL3581650T3 (pl) 2008-09-15 2009-09-15 Zmutowany polipeptyd czynnika ix, jego zastosowania i sposób jego wytwarzania

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL19174517.3T PL3581650T3 (pl) 2008-09-15 2009-09-15 Zmutowany polipeptyd czynnika ix, jego zastosowania i sposób jego wytwarzania

Country Status (16)

Country Link
US (11) US9249405B2 (pl)
EP (5) EP4219547A3 (pl)
CA (1) CA2737094C (pl)
DK (2) DK2337849T3 (pl)
ES (2) ES2940323T3 (pl)
FI (2) FI3581650T3 (pl)
FR (1) FR23C1028I1 (pl)
HK (1) HK1244507A1 (pl)
HR (2) HRP20230259T1 (pl)
HU (2) HUE061345T2 (pl)
LT (2) LT3581650T (pl)
PL (2) PL2337849T3 (pl)
PT (1) PT3581650T (pl)
SI (1) SI3581650T1 (pl)
TR (1) TR201813067T4 (pl)
WO (1) WO2010029178A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3581650T (pt) 2008-09-15 2023-03-08 Uniqure Biopharma B V Mutante de polipéptido de fator ix, as suas utilizações e um método para a sua produção
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
JP6363600B2 (ja) 2012-07-25 2018-07-25 カタリスト・バイオサイエンシーズ・インコーポレイテッドＣａｔａｌｙｓｔ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 修飾第ｘ因子ポリペプチドおよびその使用
EP4223772A3 (en) 2013-02-15 2023-10-18 Bioverativ Therapeutics Inc. Optimized factor viii gene
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
CN108138159A (zh) 2015-06-23 2018-06-08 费城儿童医院 经修饰的因子ix、以及用于基因转移到细胞、器官和组织的组合物、方法和用途
PT3411478T (pt) 2016-02-01 2022-09-13 Bioverativ Therapeutics Inc Genes do fator viii otimizados
EP3491008A2 (en) 2016-07-26 2019-06-05 BioMarin Pharmaceutical Inc. Novel adeno-associated virus capsid proteins
CN106497949A (zh) * 2016-10-14 2017-03-15 上海交通大学医学院附属瑞金医院 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用
WO2018217731A1 (en) 2017-05-22 2018-11-29 Baxalta Incorporated Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia b
CA3069194A1 (en) 2017-07-10 2019-01-17 Uniqure Ip B.V. Means and methods for aav gene therapy in humans
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
US11739345B2 (en) 2018-05-09 2023-08-29 Biomarin Pharmaceutical Inc. Methods of treating phenylketonuria
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
SG11202010832YA (en) 2018-05-14 2020-11-27 Biomarin Pharm Inc Stable expression of aav vectors in juvenile subjects
CN112739818A (zh) * 2018-08-20 2021-04-30 Ucl商业有限责任公司 编码因子ix的核苷酸
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
EP4362971A1 (en) * 2021-07-01 2024-05-08 CSL Behring Lengnau AG Factor ix subcutaneous administration with enhanced safety

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5223408A (en) 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
GB9408717D0 (en) 1994-05-03 1994-06-22 Biotech & Biolog Scien Res DNA sequences
US6227618B1 (en) 1996-02-23 2001-05-08 Schukra Usa, Inc. Cable attachment for a lumbar support
JP3553970B2 (ja) 1996-06-11 2004-08-11 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 組換え血液凝固プロテアーゼ
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
DE69841459D1 (en) 1997-02-14 2010-03-11 American Nat Red Cross Expression des active human factor ix im brustdrüsengewebe transgener tiere
US6531298B2 (en) 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US7109170B2 (en) 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
WO2001070763A1 (en) 2000-03-22 2001-09-27 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
US20040133930A1 (en) 2002-03-11 2004-07-08 Cooper Julian D. Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
EP1427820A2 (en) 2001-09-04 2004-06-16 MERCK PATENT GmbH Modified factor ix
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US20040009151A1 (en) 2002-04-04 2004-01-15 Kay Mark A. Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal
US20060292117A1 (en) * 2002-04-17 2006-12-28 Loiler Scott A Improved rAAv vectors
JP5376747B2 (ja) 2002-10-02 2013-12-25 カタリスト バイオサイエンシーズ， インコーポレイテッド 改変された特異性を有するプロテアーゼを作製する方法およびスクリーニングする方法
SI2277996T1 (sl) * 2003-05-21 2014-12-31 Genzyme Corporation Postopki za izdelavo pripravkov rekombinantnih AAV virionov v bistvu brez praznih kapsid
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
ATE469216T1 (de) 2004-08-17 2010-06-15 Csl Behring Gmbh Modifizierte vitamin-k-abhängige polypeptide
EP1627771B1 (de) 2004-08-19 2008-10-15 Gerd Bär Hubladebühne mit querverschiebbarem Verbindungsrohr
WO2006031226A1 (en) 2004-09-13 2006-03-23 Saint Louis University Region of factor ixa protease domain that interacts with factor viiia and methods therefor
ES2436741T3 (es) * 2004-09-22 2014-01-07 St. Jude Children's Research Hospital Expresión mejorada de Factor IX en vectores de terapia génica
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
ES2385837T3 (es) 2004-12-15 2012-08-01 The University Of North Carolina At Chapel Hill Vectores quiméricos
CN101340928B (zh) 2005-10-21 2011-12-21 催化剂生物科学公司 抑制补体激活的修饰的蛋白酶
WO2007059473A2 (en) * 2005-11-12 2007-05-24 Introgen Therapeutics, Inc. Methods for the production and purification of adenoviral vectors
JP5526332B2 (ja) 2005-12-21 2014-06-18 シーエヌジェイ ホールディングス，インコーポレイテッド 組み換え法によって生物活性ビタミンｋ依存性タンパク質を製造する方法
WO2007089632A2 (en) 2006-01-27 2007-08-09 The University Of North Carolina At Chapel Hill Heparin and heparan sulfate binding chimeric vectors
US7375084B2 (en) * 2006-03-07 2008-05-20 Baxter International Inc. Highly phosphorylated and sulfated recombinant factor IX
WO2007110231A2 (en) 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
EP2007795B1 (en) * 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
JP5479087B2 (ja) * 2006-04-07 2014-04-23 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム アデノ随伴ウイルスファージ粒子に関する方法および組成物
US20090252720A1 (en) 2006-05-24 2009-10-08 Novo Nordisk Health Care Ag Prolonged FIX Analogues and Derivatives
US20070280906A1 (en) * 2006-06-03 2007-12-06 Ognjen Petras Method to generate mirrored adenoassociated viral vectors
TW200804416A (en) * 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
EP2037892B1 (en) 2006-06-19 2015-03-18 Asklepios Biopharmaceutical, Inc. Modified factor viii and factor ix genes and vectors for gene therapy
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
WO2008092643A2 (en) 2007-02-01 2008-08-07 Baxter International Inc. Improved fix-mutant proteins for hemophilia b treatment
WO2008119815A1 (en) 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
US20100137211A1 (en) 2007-04-11 2010-06-03 Monahan Paul E Methods and compositions for intra-articular coagulation proteins
BRPI0705943A2 (pt) 2007-04-19 2008-12-09 Nautilus Biotech formulaÇÕes de dosagem oral de polipeptÍdeos resistentes À protease e usos das mesmas para tratamento
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
CA2702363A1 (en) 2007-10-15 2009-04-23 The University Of North Carolina At Chapel Hill Human factor ix variants with an extended half life
MX2010011345A (es) * 2008-04-16 2011-02-23 Bayer Healthcare Llc Polipeptidos modificados del factor ix y usos de los mismos.
CN102065887A (zh) 2008-04-16 2011-05-18 拜耳医药保健有限公司 因子ix的定点修饰
CN102105582A (zh) 2008-04-21 2011-06-22 诺沃-诺迪斯克有限公司 高糖基化人凝血因子ix
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
PT3581650T (pt) 2008-09-15 2023-03-08 Uniqure Biopharma B V Mutante de polipéptido de fator ix, as suas utilizações e um método para a sua produção
WO2010151736A1 (en) 2009-06-25 2010-12-29 The University Of North Carolina At Chapel Hill Chimeric factor vii molecules
KR20120060209A (ko) 2009-07-31 2012-06-11 바이엘 헬스케어 엘엘씨 변형된 인자 ｉｘ 폴리펩티드 및 그의 용도
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
US10398787B2 (en) 2012-10-26 2019-09-03 Vrije Universiteit Brussel Vectors for liver-directed gene therapy of hemophilia and methods and use thereof
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
EP3270944B1 (en) 2015-03-17 2019-10-23 Vrije Universiteit Brussel Optimized liver-specific expression systems for fviii and fix
CN108138159A (zh) 2015-06-23 2018-06-08 费城儿童医院 经修饰的因子ix、以及用于基因转移到细胞、器官和组织的组合物、方法和用途
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods for their preparation and use

Also Published As

Publication number Publication date
US20110244550A1 (en) 2011-10-06
US20220002702A1 (en) 2022-01-06
US9982248B2 (en) 2018-05-29
US20200199564A1 (en) 2020-06-25
EP4032979B1 (en) 2024-05-01
CA2737094A1 (en) 2010-03-18
EP2337849A1 (en) 2011-06-29
DK2337849T3 (en) 2018-10-01
US20210238573A1 (en) 2021-08-05
WO2010029178A1 (en) 2010-03-18
PT3581650T (pt) 2023-03-08
HRP20181442T1 (hr) 2018-12-14
CA2737094C (en) 2018-02-20
PL3581650T3 (pl) 2023-05-22
SI3581650T1 (sl) 2023-06-30
HRP20230259T1 (hr) 2023-04-28
EP4219547A2 (en) 2023-08-02
LT3581650T (lt) 2023-05-10
US20180258413A1 (en) 2018-09-13
US20220090042A1 (en) 2022-03-24
TR201813067T4 (tr) 2018-09-21
US20200231958A1 (en) 2020-07-23
CA2737094F (en) 2010-03-18
HK1244507A1 (zh) 2018-08-10
FIC20230026I1 (fi) 2023-07-25
US20160122740A1 (en) 2016-05-05
HUS2300024I1 (hu) 2023-08-28
DK3581650T3 (da) 2023-03-13
EP3252157A1 (en) 2017-12-06
ES2687038T3 (es) 2018-10-23
US10465180B2 (en) 2019-11-05
US20210214704A1 (en) 2021-07-15
FI3581650T3 (fi) 2023-03-23
LTPA2023521I1 (pl) 2023-08-25
EP3581650A2 (en) 2019-12-18
EP4032979A1 (en) 2022-07-27
US20200190498A1 (en) 2020-06-18
US20170355973A1 (en) 2017-12-14
ES2940323T3 (es) 2023-05-05
EP3581650A3 (en) 2020-03-25
HUE061345T2 (hu) 2023-06-28
EP4219547A3 (en) 2023-10-18
FR23C1028I1 (fr) 2023-10-06
EP3581650B1 (en) 2022-12-28
US9249405B2 (en) 2016-02-02
EP2337849B1 (en) 2018-06-13

Similar Documents

Publication Publication Date Title
HUS2300024I1 (hu) IX-es faktor polipeptid mutáns, alkalmazásai és eljárás elõállítására
EP2246415A4 (en) IMPROVED PROMOTER AND METHOD FOR PRODUCING L-LYSINE USING THE PROMOTER
ZA200908428B (en) Method for the production of a component, and component
PL2080736T3 (pl) Aerożele węglowe, sposób ich wytwarzania i ich zastosowanie
HK1159151A1 (en) Carbon black, method for the production thereof, and use thereof
IL204555A0 (en) (carboxylalkylene-phenyl) phenyl-oxalamides, method for the production thereof, and use of same as a medicatment
EP2196534A4 (en) RECOMBINANT MICROORGANISM AND METHOD FOR PRODUCING POLY GAMMA GLUTAMINE ACID
ZA201007720B (en) Production method
EP2130909A4 (en) METHOD OF PRODUCING TOOTH AND TOOTH PRODUCED BY THE METHOD
EP2295563A4 (en) B-AMYLASE, ENCODING GENE AND PROCESS FOR PRODUCING THE SAME
HUE044749T2 (hu) Javított promóter és javított promótert alkalmazó, L-lizin elõállítására szolgáló eljárás
IL233881A (en) Yeast genetically modified yeasts for squalene production, a genetically modified yeast yeast preparation and method for making them
EP2189476A4 (en) NOVEL POLYPEPTIDE AND MANUFACTURING METHOD THEREFOR
EP2256194A4 (en) FLOCCULATING YEAST AND METHOD FOR PRODUCING THE SAME
HK1140967A1 (en) Vesicle-containing composition, and method for production thereof
ZA200901945B (en) Hydrogen production method
EP2374776A4 (en) METHOD FOR MANUFACTURING CARBON MATERIAL, AND CARBON MATERIAL
EP2384388A4 (en) Configurations and methods for improved subsea production control
ZA201200528B (en) Novel alkoxyenones and enaminoketones and a method for the production thereof
HRP20150188T1 (en) Assembly and method for paper production
PL2288500T3 (pl) Laminat i sposób jego wytwarzania
EP2327789A4 (en) NEW COMPOUND SIGNAMYCIN, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF
PL2262894T3 (pl) Rekombinowany mikroorganizm i sposób wytwarzania l-lizyny
GB0822093D0 (en) Improved phospholid and method for its production
GB0615139D0 (en) Alternative membrane production method